07:00 , Aug 22, 2016 |  BC Week In Review  |  Clinical News

Lucassin terlipressin: Phase III started

Mallinckrodt began the double-blind, placebo-controlled, North American Phase III CONFIRM trial to evaluate 1 mg IV Lucassin every 6 hours in about 300 patients. Lucassin is approved outside the U.S. and Canada to treat Type...
07:00 , Jun 15, 2015 |  BC Week In Review  |  Clinical News

Akynzeo netupitant/palonosetron regulatory update

The European Commission approved Akynzeo netupitant/palonosetron to prevent acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy or moderately emetogenic cancer chemotherapy. The product is a fixed-dose combination of 300 mg...
07:00 , Mar 30, 2015 |  BC Week In Review  |  Clinical News

Akynzeo netupitant/palonosetron regulatory update

EMA’s CHMP recommended approval of Akynzeo netupitant/palonosetron (NEPA) from Helsinn to prevent acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy or with moderately emetogenic cancer chemotherapy. The product is a...
07:00 , Oct 13, 2014 |  BC Week In Review  |  Clinical News

Akynzeo netupitant/palonosetron regulatory update

FDA approved Akynzeo netupitant/palonosetron from Helsinn to treat nausea and vomiting in patients undergoing cancer chemotherapy. The product is a fixed-dose combination of 300 mg netupitant, a neurokinin 1 (NK1) substance P receptor antagonist, and...
07:00 , Apr 7, 2014 |  BC Week In Review  |  Company News

AQTIS Medical, Sinclair IS Pharma deal

Sinclair acquired AQTIS for €16.6 million ($22.8 million) up front in cash. AQTIS is also eligible for up to €20 million ($27.5 million) in sales milestones and up to €10 million ($13.8 million) in U.S....
07:00 , Mar 17, 2014 |  BC Week In Review  |  Clinical News

Flammacerium cerium nitrate/silver sulfadiazine regulatory update

Sinclair said FDA granted Orphan Drug designation to Flammacerium cerium nitrate/silver sulfadiazine cream to treat patients with severe dermal burns. The company said the product is used in cases where surgical excision and grafting are...
08:00 , Feb 10, 2014 |  BC Week In Review  |  Company News

Sinclair IS Pharma, GlaxoSmithKline deal

Sinclair acquired Atlean from GlaxoSmithKline's Stiefel dermatology business for an undisclosed amount. Atlean - a combination of a collagen stimulator and hyaluronic acid filler - is a dermal filler. Sinclair said Atlean complements its existing...
08:00 , Feb 3, 2014 |  BC Week In Review  |  Clinical News

NEPA regulatory update

EMA accepted for review an MAA from Helsinn for NEPA to prevent acute and delayed chemotherapy-induced nausea and vomiting (CINV). The product is also under review for the indication in the U.S., where it has...
08:00 , Feb 3, 2014 |  BC Week In Review  |  Company News

Pharmavital, Sinclair IS Pharma deal

Sinclair acquired Pharmavital's Obvieline Laboratories S.A. subsidiary and said it will acquire distribution rights to Obvieline's Perfectha dermal fillers in Brazil and Russia from Pharmavital. Sinclair said the deal is valued at up to €32.2...
08:00 , Jan 6, 2014 |  BC Week In Review  |  Company News

Ikaria, Madison Dearborn Partners deal

On Dec. 24, 2013, private equity firm Madison Dearborn said it will acquire the majority stake in the commercial business of Ikaria in a deal the parties said values the business at about $1.6 billion....